BACKGROUND: Lung cancer is a leading cause of death and hospitalization for patients with COPD. A detailed understanding of which clinical features of COPD increase risk is needed.
Lung cancer is one of the leading causes of death and hospitalization for individuals with COPD. 1 The causal relationship between COPD and lung cancer needs to be further studied to understand the pathogenesis of lung cancer in this setting. Recent analysis of airway obstruction and emphysema in lung cancer screening cohorts has added to our knowledge of COPD and lung cancer risk. It is clear that the degree of airway obstruction is a predictor of lung cancer. This theory is true when controlled for confounding risk factors associated with cigarette smoking (ie, current smoking status, duration, intensity, years since quitting). In a subgroup analysis of subjects within the National Lung Cancer Screening Trial (NLST) with spirometric data available at the time of enrollment, a 2.15-fold increase occurred in lung cancer incidence for those with airway obstruction. 2 Several meta-analyses have also found a strong correlation between degree of airway obstruction and a diagnosis of lung cancer. 3, 4 The association of emphysema and lung cancer has been less clear. Early studies of quantitative emphysema and lung cancer risk were confounded by small case numbers, low-dose CT scans, and the novel technology of quantitative emphysema analysis. 5, 6 However, subsequent research using visually assessed emphysema has validated this biomarker as a risk for lung cancer. Studies of the Pittsburgh Lung Screening Study identified visual emphysema on CT imaging as predictive of lung cancer independent of the severity of airway obstruction, 7 and the COPD-Lung Cancer Screening
Score validated the visual presence of emphysema as an independent variable for risk of lung cancer. 8, 9 The risk of lung cancer associated with other clinical aspects of COPD, such as acute respiratory exacerbations, has not been thoroughly investigated. Respiratory exacerbations are characterized by lung inflammation, which is believed to be central to the pathogenesis of lung cancer in this setting. 10 To further study the relationship between COPD phenotypes such as airflow obstruction, emphysema, and frequent respiratory exacerbations, we followed up subjects from the Genetic Epidemiology of COPD (COPDGene) Study, one of the largest studies to date of smokers with and without COPD. 11 The study enrolled older, current and former smokers, most of whom were at high risk for developing lung cancer. With longitudinal follow-up up to 8 years, we were able to analyze features of COPD that predict lung cancer.
Patients and Methods
This protocol was approved by the institutional review board at each institution, and all participants provided written informed consent. The study population was recruited from participants in the COPDGene Study (http://www.copdgene.org/).
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A detailed description of methods can be found in e-Appendix 1.
Exacerbations and Imaging
At the time of enrollment, subjects were asked on self-administered questionnaires, "Have you had a flare-up of your chest trouble in the last 12 months?" Zero exacerbations were recorded if the subject answered no. If the answer was yes, the subjects were asked how many episodes required either additional antibiotic or steroid medication, consultation with a physician, or hospital admission. The total number of such episodes was the exacerbation frequency.
A high-resolution chest CT scan was performed at the time of study enrollment. Visual analysis for centrilobular and paraseptal emphysema was performed by two trained readers, with discordant readings adjudicated by a thoracic radiologist. 12 Parenchymal emphysema was scored on a scale of 0 to 5: none, trace, mild, moderate, confluent, and advanced-destructive. 13 Paraseptal emphysema was scored into three categories: none, mild, and substantial.
Lung cancer cases were identified through longitudinal follow-up and collection of death certificates. During follow-up, if a subject selfreported a new diagnosis of lung cancer, this report was verified by review of medical records. Control subjects were those subjects with no lung cancer reported throughout longitudinal follow-up, and, for those with a death certificate, no recorded lung cancer.
Statistical Analysis
Unless otherwise specified, analyses were conducted by using R version 3.3.2 (R Development Core Team). Case and control subjects were matched 1:4, for known lung cancer risk factors, including age (within 5 years), race, sex, smoking status (current/former), packyears of smoking exposure (within 10 pack-years), and years since quitting (within 10 years). Logistic regression with age, sex, race, smoking status, smoking pack-years, years since quitting, and FEV 1 / FVC as covariates was used to determined which other variables collected at the time of enrollment were associated with a new lung cancer diagnosis during longitudinal follow-up. Those variables found to be significant were used to generate a single multivariate model for lung cancer diagnosis. A second model was created by using just the lung cancer cases to identify baseline variables associated with histopathologic type. Additional baseline variables considered included the following: quantitative emphysema, as a continuous variable using either percent low attenuation area (LAA%) less than -950 Hounsfield units (HU), log of LAA%, or 15th percentile of the lung density; emphysema as a dichotomized variable (normal vs abnormal [> 5% LAA]); emphysema as an ordinal variable (visual emphysema [scored as none or trace]); and those with visual emphysema (scored as mild to advanced). Kaplan-Meier analysis was used to determine time to lung cancer diagnosis. The G-rho family of tests was used to determine hazard ratios (HRs) for time remaining lung cancer free.
Results
A total of 169 subjects were identified as being diagnosed with lung cancer during the longitudinal follow-up of the COPDGene Study, with an average follow-up of 5.7 years (AE1.87 years) (e- Fig 1) . These case subjects were matched (for age, race, sex, smoking status, average smoking pack-years, and years since quitting smoking) 1:4 with 671 control subjects with no reported lung cancer diagnosis; five subjects only had three matched control subjects. The characteristics of the case and control subjects at the time of study enrollment are reported in Table 1 . Forty-nine percent of lung cancer cases were identified in women, and 21% of cases were in African-American subjects. Compared with the control group, subjects who were diagnosed with lung cancer had more severe airway obstruction on baseline spirometry, as measured by FEV 1 /FVC and percent predicted FEV 1 . They also had more severe emphysema on both quantitative and visual assessment. In addition, subjects with a subsequent lung cancer diagnosis had more acute respiratory exacerbations in the year prior to enrollment and a lower BMI.
Of the 169 verified cases of lung cancer, 98 were confirmed non-small cell lung cancer (NSCLC), and 18 were small-cell lung cancer (SCLC) ( Table 2 ). Of the 79 NSCLC cases with staging information available, 42% were stage I at the time of diagnosis, and 18% had advanced (stage IV) disease; 62% of the NSCLC cases were adenocarcinoma. Analysis of mortality within the cases of lung cancer shows that those with an advanced Global Initiative for Chronic Lung Disease stage had inferior survival (Fig 1) . Forty-six (79%) of the NSCLC cases and 10 (71%) of the SCLC cases with death certificates available for review had lung cancer listed as a cause of death.
Factors Associated With Lung Cancer
When matched for age, race, sex, smoking status, packyears, and time since quitting tobacco, univariate predictors of a lung cancer diagnosis included respiratory exacerbations in the 12 months prior to enrollment, use of inhaled corticosteroid or tiotropium or combination of corticosteroid with tiotropium, decreased percent predicted FEV 1 , the presence of quantitative and visual emphysema, the presence of quantitative gas trapping, Tables 1 and 2 ).
According to Kaplan-Meier analysis of lung cancer, case subjects with documented diagnosis dates (n ¼ 94) and their matched control subjects who reported one or more respiratory exacerbations had an increased risk of lung cancer compared with subjects without a reported exacerbation (HR, 2.75 [95% CI, 1.59-4.75]; P < .001) (Fig 2) . Analysis of case subjects with a diagnosis date and visual emphysema assessment (n ¼ 82) and matched control subjects was also performed. Visual emphysema was also significantly associated with the risk of a lung cancer diagnosis (HR, 3.0 [95% CI, .59]; P < .001) (Fig 3) , with the highest risk in those with moderate (HR, 3.13 [95% CI, ) to confluent (HR, 2.48 [95% CI, .57]) emphysema (Fig 4) .
Factors Associated in a Multivariate Model
Multivariate analysis with logistic regression was performed on each variable with the earlier described covariates (e- Table 3 ). Factors that were independently associated with lung cancer during follow-up were used to generate a logistic regression model ( This analysis was also performed on case subjects and matched control subjects with COPD (FEV 1 /FVC < 0.7) (e- Table 5 and Table 5 ).
Although qualitative assessment of emphysema was associated with lung cancer risk in multivariate modeling, quantitative measurements, including emphysema, gas trapping, and airway wall thickness, were not. This outcome was also true of inhaled respiratory medications, including corticosteroids and tiotropium.
Discussion
The COPDGene Study, one of the largest spirometry and CT imaging-based analyses of current and former smokers, evaluates multiple sub-phenotypes of COPD such as airflow obstruction, emphysema, and acute Figure 1 -Kaplan-Meier curve for lung cancer diagnosis, comparing subjects with no acute respiratory exacerbations reported in the 12 months prior to study enrollment (n ¼ 387) vs those with one or more reported exacerbations (n ¼ 87). Subjects were followed up for 8 years; those who died without lung cancer or were lost to follow-up were censored as marked. HRs are based on an unadjusted analysis of time to lung cancer diagnosis. This analysis was limited to cases with an annotated lung cancer diagnosis date and the matched control subjects. HR ¼ hazard ratio.
respiratory exacerbations. In the present study, we found that the severity of airflow obstruction is an independent risk factor for lung cancer, both in the larger COPDGene cohort as well as in those with COPD. We also validate several publications that report the presence and degree of visual emphysema (another marker of smoking-induced lung injury) increase the risk of lung cancer independent of airflow obstruction. 7, 9, 12, 15, 16 For the first time, this study identifies that frequency of acute respiratory exacerbations also increases the risk of lung cancer independent of airflow obstruction and extent of emphysema. Whether acute respiratory exacerbations contribute to the pathogenesis of lung cancer, or are only a marker of the underlying smoking-induced injury and inflammation, is unknown. We also found that a history of acute respiratory exacerbations increased the risk of SCLC histology.
Chronic inflammation is believed to be central to the pathogenesis of lung cancer in the setting of COPD.
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The presence of chronic inflammation is associated with respiratory exacerbations, and the risks of both lung cancer and COPD exacerbations diminish with increased duration of smoking cessation. 17, 18 Those with frequent exacerbations are believed to represent a unique sub-phenotype of patients with COPD. For instance, we have previously shown that prior exacerbations of COPD are predictive of future exacerbations. 19 The existence of a COPD exacerbator phenotype is supported by the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, which identified a subgroup of patients with COPD predisposed to frequent acute exacerbations of COPD. In a study with short longitudinal follow-up, it may be possible that subjects with a history of frequent respiratory exacerbations have a higher incidence of lung cancer diagnosis due to incidental findings on chest imaging performed in the setting of a medical evaluation of respiratory symptoms. However, the long interval of Case and control subjects were matched for age, race, sex, smoking status, smoking pack-years, and years since quitting. HU ¼ Hounsfield units; LABA ¼ long-acting beta-agonist; Perc15 ¼ 15th percentile of lung density. See Table 1 legend for expansion of other abbreviations.
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follow-up and a high rate of lung cancer as cause of death among the cases argue against overdiagnosis due to increased imaging. Also, subjects with frequent acute exacerbations of COPD were more like to have a diagnosis of SCLC, the incidence of which has not been altered by routine imaging in the setting of CT screening. 20 Our analysis was performed on acute respiratory exacerbations reported for the 12-month period prior to COPDGene study enrollment. We did not analyze exacerbations during the COPDGene longitudinal follow-up period, as the association would be confounded by acute respiratory exacerbations caused by lung cancer and its treatment.
In the present study, the risk of lung cancer increased with severity of visual emphysema, although analysis of the most severe cases (advanced-destructive Figure 2 -Kaplan-Meier curve comparing subjects with no to trace visual centrilobular emphysema (n ¼ 162) vs those with mild to advanced visual emphysema (n ¼ 250). Subjects were followed for 8 years for a lung cancer diagnosis. Subjects who died without lung cancer or were lost to follow-up were censored as marked. HRs are based on an unadjusted analysis of time to lung cancer diagnosis. This analysis was limited to those cases with annotated lung cancer diagnosis dates, complete visual emphysema assessment, and the matched control subjects. See Figure 1 legend for expansion of abbreviation. emphysema) was limited by small subject numbers. As seen in other studies, quantitative emphysema was not associated with a diagnosis of lung cancer. There is known discordance between visual and quantitative detection of emphysema; this discordance occurs because quantitative evaluation using LAA-950HU or other methods provides a relatively crude global index of lung density that can be affected by image noise, and may not detect mild or localized emphysema. 21 Because visual emphysema grading is less sensitive to image noise, it more precisely discriminates between subjects with and without emphysema. The results of this study are congruent with several previous articles which have shown that although visual evidence of emphysema is associated with lung cancer, most have found that there is no association with quantitative emphysema. 5, 7, 16, [22] [23] [24] Because the incidence of lung cancer was not a primary outcome of the COPDGene Study, this study is limited by missing clinical data and subject recall related to previous exacerbations. Although all control subjects were screened to ensure that no lung cancer was reported, false-negative findings may be present. Another limitation is that 24% of the COPDGene subjects had < 5 years of follow-up, and 10% of subjects had no follow-up. Thus, we expect that some lung cancer diagnoses are unreported, and survival outcomes of these subjects are unknown. The majority of cases in this study were identified by review of death Case and control subjects were matched for age, race, sex, smoking status, smoking pack-years, and years since quitting. See Table 1 legend for expansion of abbreviation.
certificates (e -Fig 2) , which could explain the high mortality rate (Fig 1) .
Conclusions
Following the publication of the results of the NLST showing an improvement in overall mortality from CT lung cancer screening, multiple organizations recommended lung cancer screening. 20 These guidelines were predominantly based on the NLST entry criteria: age 55 to 74 years with $ 30 pack-years of smoking history and either currently smoking or quit within the previous 15 years. [25] [26] [27] [28] The data are limited to inform screening guidelines in those with COPD, 29 including
those with advanced disease who should be excluded due to lack of benefit and those with high risk features who should be included. As our understanding of COPD phenotypes and lung cancer risk continues to expand, the lung cancer screening guidelines should also evolve. Our study suggests that in addition to airflow obstruction, visual emphysema and a history of acute respiratory exacerbations should also be considered in future lung cancer screening studies.
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